Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-12-13 DOI:10.1080/14796694.2024.2433407

Congcong Wang, Yutian Li, Yu Zhang, Guoqiang Wang, Xinfeng Liu, Yingying Zhang, ZengHua Wang, Zengmei Si, Fengqi Li, Gaixia Lu, Renfei Wang, Xufu Wang

{"title":"Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer.","authors":"Congcong Wang, Yutian Li, Yu Zhang, Guoqiang Wang, Xinfeng Liu, Yingying Zhang, ZengHua Wang, Zengmei Si, Fengqi Li, Gaixia Lu, Renfei Wang, Xufu Wang","doi":"10.1080/14796694.2024.2433407","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the prognostic value of pre-ablation stimulated thyroglobulin (ps-Tg) in children and adolescents with persistent differentiated thyroid cancer (DTC) following initial radioiodine therapy (RAI).Materials & methods: Patients were classified into \"no clinical evidence of disease\" (NED), \"biochemical persistent disease\" (BPD), and \"structural/functional persistent disease\" (S/FPD) groups, based on their therapeutic response to initial RAI. BPD patients were further categorized as incomplete response (IR) or Non-IR; S/FPD patients were categorized as remission or Non-remission. Receiver operating characteristic (ROC) curves were used to assess the predictive value of ps-Tg for long-term prognosis. Univariate and multivariate regression analyses were performed to identify risk factors for IR in BPD group and Non-remission in S/FPD group.Results: In total, 130 patients were included, with NED (32), BPD (61), and S/FPD (37) patients. Multivariate analysis identified therapeutic response to initial RAI as the only independent predictor of IR in the BPD group. ROC analysis determined an optimal ps-Tg threshold of 112.40 ng/mL for predicting Non-remission in S/FPD patients. Multivariate analysis further confirmed that ps-Tg > 112.4 ng/mL was significantly associated with Non-remission.Conclusions: Findings indicate ps-Tg as a valuable predictor of long-term prognosis in children and adolescents with persistent DTC post initial RAI.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3463-3470"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776856/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2433407","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate the prognostic value of pre-ablation stimulated thyroglobulin (ps-Tg) in children and adolescents with persistent differentiated thyroid cancer (DTC) following initial radioiodine therapy (RAI).

Materials & methods: Patients were classified into "no clinical evidence of disease" (NED), "biochemical persistent disease" (BPD), and "structural/functional persistent disease" (S/FPD) groups, based on their therapeutic response to initial RAI. BPD patients were further categorized as incomplete response (IR) or Non-IR; S/FPD patients were categorized as remission or Non-remission. Receiver operating characteristic (ROC) curves were used to assess the predictive value of ps-Tg for long-term prognosis. Univariate and multivariate regression analyses were performed to identify risk factors for IR in BPD group and Non-remission in S/FPD group.

Results: In total, 130 patients were included, with NED (32), BPD (61), and S/FPD (37) patients. Multivariate analysis identified therapeutic response to initial RAI as the only independent predictor of IR in the BPD group. ROC analysis determined an optimal ps-Tg threshold of 112.40 ng/mL for predicting Non-remission in S/FPD patients. Multivariate analysis further confirmed that ps-Tg > 112.4 ng/mL was significantly associated with Non-remission.

Conclusions: Findings indicate ps-Tg as a valuable predictor of long-term prognosis in children and adolescents with persistent DTC post initial RAI.

查看原文本刊更多论文

消融前促甲状腺球蛋白对儿童和青少年分化型甲状腺癌的预后价值。

目的：探讨消融前促甲状腺球蛋白（ps-Tg）在儿童和青少年持续性分化型甲状腺癌（DTC）初次放射碘治疗（RAI）后的预后价值。材料与方法：根据患者对初始RAI的治疗反应，将患者分为“无疾病临床证据”（NED）、“生化持续性疾病”（BPD）和“结构/功能性持续性疾病”（S/FPD）组。BPD患者进一步分为不完全缓解（IR）和非IR；S/FPD患者分为缓解型和非缓解型。采用受试者工作特征（ROC）曲线评价ps-Tg对远期预后的预测价值。通过单因素和多因素回归分析确定BPD组和S/FPD组IR的危险因素。结果：共纳入130例患者，其中NED（32例），BPD（61例），S/FPD（37例）。多变量分析表明，对初始RAI的治疗反应是BPD组IR的唯一独立预测因子。ROC分析确定预测S/FPD患者非缓解的最佳ps-Tg阈值为112.40 ng/mL。多因素分析进一步证实，ps-Tg > 112.4 ng/mL与非缓解显著相关。结论：研究结果表明，ps-Tg是原发性RAI后持续性DTC儿童和青少年长期预后的有价值的预测因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.